EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

Emilio Guillén-Mancina, María Del Rosario García-Lozano iD, Estefanía Burgos-Morón iD, Sarah Mazzotta iD, Pablo Martínez-Aguado, José Manuel Calderón-Montaño iD, José Manuel Vega-Pérez, Miguel López-Lázaro iD, Fernando Iglesias-Guerra, Margarita Vega-Holm iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242317041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Emilio Guillén-Mancina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most common type of cancer in women. Although current treatments can increase patient survival, they are rarely curative when the disease is advanced (metastasis). Therefore, there is an urgent need to develop new cytotoxic drugs with a high selectivity toward cancer cells. Since repurposing approved drugs for cancer therapy has been a successful strategy in recent years, in this study, we screened a library of antiviral piperazine-derived compounds as anticancer agents. The compounds included a piperazine ring and aryl urea functions, which are privileged structures present in several anti-breast cancer drugs. The selective cytotoxic activity of a set of thirty-four 4-acyl-2-substituted piperazine urea derivatives against MCF7 breast cancer cells and MCF 10A normal breast cells was determined. Compounds 31, 32, 35, and 37 showed high selective anticancer activity against breast cancer cells and were also tested against another common type of cancer, non-small cell lung cancer (A549 lung cancer cells versus MRC-5 lung normal cells). Compounds 35 and 37 also showed selectivity against lung cancer cells. These results suggest that compounds 35 and 37 may be promising hit compounds for the development of new anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsFemaleHumansDrug RepositioningPiperazineUreaStructure-Activity RelationshipDrug Screening Assays, AntitumorCell ProliferationMolecular StructureMCF-7 Cells

Stichwörter der Autor:innen

aryl ureabreast cancercellular viabilitypiperazineselective cytotoxic activity

Substanzen

Antineoplastic AgentsPiperazineUrea

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.
  • Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain.
  • Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC, University of Seville, 41013 Seville, Spain.
  • Department of Chemistry, University of Milan, 20133 Milan, Italy.
  • Infectious Diseases and Microbiology Clinical Unit, University Hospital Virgen Macarena, 41009 Seville, Spain.
  • Departament of Medicine, School of Medicine, University of Seville, 41012 Seville, Spain.

ORCID-Profile: María Del Rosario García-Lozano, Estefanía Burgos-Morón, Sarah Mazzotta, José Manuel Calderón-Montaño, Miguel López-Lázaro, Margarita Vega-Holm

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • Instituto de Salud Carlos III
  • Junta de Andalucía
  • Universidad de Sevilla
  • Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos-Proyectos I + D + i
  • Ministerio de Economía y Competitividad, Instituto de Salud Carlos III
  • University of Seville
  • “VI Plan Propio de Investigación y Transferencia”

Zitieren

APA

Guillén-Mancina, E., García-Lozano, M. D. R., Burgos-Morón, E., Mazzotta, S., Martínez-Aguado, P., Calderón-Montaño, J. M., Vega-Pérez, J. M., López-Lázaro, M., Iglesias-Guerra, F., & Vega-Holm, M. (2023). Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242317041

Vancouver

Guillén-Mancina E, García-Lozano MDR, Burgos-Morón E, Mazzotta S, Martínez-Aguado P, Calderón-Montaño JM, et al. Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242317041

BibTeX
@article{GuillnMancina2023,
  author = {Guillén-Mancina, Emilio and García-Lozano, María Del Rosario and Burgos-Morón, Estefanía and Mazzotta, Sarah and Martínez-Aguado, Pablo and Calderón-Montaño, José Manuel and Vega-Pérez, José Manuel and López-Lázaro, Miguel and Iglesias-Guerra, Fernando and Vega-Holm, Margarita},
  title = {Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242317041}
}
Kostenlos starten →